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Summary
Background.  —  Fenﬂuramine  and  its  derivatives  have  been  associated  with  signiﬁcant  risk  of
developing  valvular  heart  disease  but  its  exact  prevalence  and  severity  are  still  debated.
Aim. —  To  evaluate  the  clinical  and  echocardiographic  characteristics  of  patients  hospitalized
in a  cardiology  centre  and  who  had  past  exposure  to  these  drugs.
Methods.  —  Between  July  2011  and  February  2012,  patients  admitted  to  the  hospitalization  and
intensive care  units  at  the  University  Centre  of  Montpellier,  France  were  questioned  about  past
exposure to  fenﬂuramine  or  its  derivatives.  In  patients  who  reported  exposure,  a  questionnaire
assessing prescribing  patterns  and  medical  history  was  proposed  and  echocardiography  per-
formed. All  of  the  usual  echocardiographic  variables  were  analysed.  We  applied  criteria  from  a
French multicentre  registry  for  diagnosis  of  drug-induced  valvulopathy:  leaﬂets  and  subvalvu-
lar apparatus  thickening  and  retraction,  leaﬂets  loss  of  coaptation,  no  calciﬁcation,  and  no
stenosis.
Abbreviations: CI, Conﬁdence interval; EROA, Effective regurgitant oriﬁce area; LVEF, Left ventricular ejection fraction; PAH, Pulmonary
rtery hypertension; VHD, Valvular heart disease.
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Results.  —  Ninety-ﬁve  patients  exposed  to  these  drugs  were  included.  The  majority  were
female (n  =  62,  65.3%),  53.2%  (n  =  50)  had  diabetes  and  90.5%  (n  =  86)  were  exposed  to  ben-
ﬂuorex. Mean  treatment  duration  was  52.3  months  (95%  conﬁdence  interval  [CI]  39.0—65.6).
Valvular regurgitations  were  observed  in  64.0%  of  patients  (n  =  57)  while  19.8%  (n  =  17)  had
pulmonary  hypertension.  Highly  probable  fenﬂuramine-induced  regurgitations  were  present
in 18.6%  (n  =  16)  of  patients,  possibly  fenﬂuramine-induced  regurgitations  in  38.2%  (n  =  34)  of
patients, and  unlikely  fenﬂuramine-induced  regurgitations  in  25.8%  (n  =  23)  of  patients.  Highly
probable  fenﬂuramine-induced  regurgitations  were  mild  to  moderate  in  severity  in  all  except
three patients.
Conclusion.  —  Considering  the  frequency  of  probable  or  possible  fenﬂuramine-induced  regurgi-
tations and  in  the  absence  of  deﬁnite  knowledge  about  the  evolution  of  drug-induced  valvular
disease, systematic  questioning  about  fenﬂuramine  use  may  be  advisable  in  hospitalized  cardiac
patients.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  La  consommation  de  dérivés  fenﬂuraminiques  a  été  associée  à  un  sur-risque  de
survenue de  lésions  valvulaires  mais  la  prévalence  et  la  sévérité  de  ces  valvulopathies  est
encore discutée.
Objectif.  —  Évaluer  les  caractéristiques  cliniques  et  échocardiographiques  des  patients  hospi-
talisés en  cardiologie  et  qui  ont  été  exposés  aux  dérivés  fenﬂuraminiques.
Méthodes.  —  Entre  juillet  2011  et  février  2012,  les  patients  hospitalisés  en  cardiologie  au  centre
universitaire  de  Montpellier  (France)  ont  été  interrogés  quant  à  une  exposition  à  un  dérivé  fen-
ﬂuraminique.  Un  questionnaire  était  remis  aux  patients  exposés  aﬁn  de  préciser  les  modalités  de
prescription  et  les  antécédents  médicaux.  Une  échocardiographie  était  réalisée  et  nous  avons
utilisé les  critères  du  Registre  multicentrique  franc¸ais  pour  le  diagnostic  de  lésions  valvulaires
d’origine toxique  liées  à  l’exposition  aux  dérivés  fenﬂuraminiques  :  épaississement  et  rétrac-
tion de  la  valve  et  de  l’appareil  sous-valvulaire,  défaut  de  coaptation,  absence  de  calciﬁcation,
et absence  de  sténose.
Résultats.  — Quatre-vingt-quinze  patients  exposés  aux  dérivés  fenﬂuraminiques  ont  été  inclus.
La majorité  d’entre  eux  étaient  des  femmes  (n  =  62,  65,3  %)  ;  53,2  %  (n  =  50)  avaient  un  diabète
sucré et  90,5  %  (n  =  86)  avaient  été  exposés  au  benﬂuorex.  La  durée  moyenne  de  traitement  était
de 52,3  mois  (IC  95  %  39,0—65,6).  Des  fuites  valvulaires  ont  été  observées  chez  64  %  des  patients
(n =  57),  tandis  que  19,8  %  (n  =  17)  avaient  une  hypertension  artérielle  pulmonaire.  Les  fuites
valvulaires  probablement  imputables  aux  dérivés  fenﬂuraminiques  concernaient  18,6  %  (n  =  16)
des patients,  les  fuites  valvulaires  possiblement  imputables  38,2  %  (n  =  34)  et  les  fuites  valvu-
laires non  imputables  25,8  %  (n  =  23).  Les  fuites  valvulaires  probablement  imputables  étaient
toutes de  sévérité  légère  à  modérée  exceptée  pour  3  cas.
Conclusions.  —  Étant  donné  la  fréquence  des  fuites  valvulaires  probablement  ou  possiblement
imputables  aux  dérivés  fenﬂuraminiques  et  en  l’absence  de  certitude  quant  au  potentiel  évo-
tutif des  lésions  valvulaires  d’origine  toxique,  la  recherche  systématique  d’une  exposition  aux
dérivés fenﬂuraminiques  pourrait  être  envisagée  en  pratique  quotidienne  pour  les  patients
hospitalisés  en  cardiologie.
©  2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
d
a
a
f
rBackground
Fenﬂuramine  and  its  derivatives  are  sympathomimetic
amines  with  an  anorectic  action  mediated  through  the  acti-
vation  of  serotoninergic  pathways  in  the  brain.  These  drugs
have  been  suspected  to  cause  valvular  heart  disease  (VHD)
[1—3]  and  pulmonary  artery  hypertension  (PAH)  [4]. Fen-
ﬂuramine  was  introduced  ﬁrst  in  France  in  1963  under  the
brand  name  Ponderal®;  then  as  the  dextrorotatory  isomer
b
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mexfenﬂuramine  in  1985  under  the  name  Isomeride®;  and
s  benﬂuorex  in  1976  under  the  name  Mediator®.  Ponderal®
nd  Isomeride® were  withdrawn  from  the  market  in  1997,
ollowed  by  Mediator® in  2009,  after  the  publication  of  case
eports  reporting  cardiovascular  adverse  drug  reactions.
In  2010  Frachon  et  al.  [1]  established  an  association
etween  benﬂuorex  and  unexplained  mitral  regurgitation.
xposure  to  benﬂuorex  was  found  in  70%  of  patients  with
itral  insufﬁciency  of  undetermined  cause  (cases)  and
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n  5.6%  of  the  control  group.  Benﬂuorex  was  associated
ith  a  high-risk  of  mitral  regurgitation  (odds  ratio  [OR]  17.1,
5%  conﬁdence  interval  [CI]  3.5—83,  P  <  0.01).  In  the  REGU-
ATE  trial  [5,6],  Derumeaux  et  al.  reported  that  minimal
alvular  abnormalities  were  detected  in  51%  of  patients
efore  any  exposure  to  benﬂuorex.  In  the  Health  Insurance
und  for  Salaried  Workers  (CNAMTS)  survey  [7],  the  adjusted
elative  risk  of  hospitalization  for  valvular  regurgitation  was
.1  times  greater  (95%  CI  2.4—4.1)  in  patients  exposed  to
enﬂuorex  and  the  risk  of  hospitalization  for  heart  valve
eplacement  was  multiplied  by  3.9  (95%  CI  2.6—6.1).  The
isk  of  developing  mitral  and  aortic  regurgitations  was  also
igher  with  benﬂuorex  exposure  (adjusted  relative  risk  2.5,
5%  CI  1.9—3.7  and  4.4,  95%  CI  3.0—6.6,  respectively).
ccording  to  Hill  et  al.  [8],  benﬂuorex  was  responsible  for
65  deaths  after  a  follow-up  of  5.5  years,  and  for  3500
ospitalizations  for  valvular  insufﬁciency  and  1750  cardiac
urgeries  after  4  years  of  follow-up.  Valvular  heart  disease
elated  to  benﬂuorex  mainly  affects  the  mitral  and/or  aortic
alves,  but  can  simultaneously  alter  the  four  valves  [3].
The  aim  of  this  single-centre  prospective  study  was  to
eport  the  clinical  characteristics  and  echocardiographic
eatures  of  patients  admitted  to  our  cardiology  department
nd  who  had  a  history  of  treatment  with  fenﬂuramine  or  its
erivatives.
ethods
ubjects
etween  July  2011  and  February  2012,  all  patients  admitted
o  the  hospitalization  unit  and  the  intensive  care  unit  of  the
niversity  Hospital  of  Montpellier  were  questioned  about
ast  exposure  to  fenﬂuramine  or  its  derivatives,  dexfenﬂu-
amine  and  benﬂuorex.
linical data
atients  who  reported  previous  exposure  to  fenﬂuramine  or
ts  derivatives  were  invited  to  complete  a  questionnaire  that
ssessed  prescribing  patterns,  medical  history  and  symp-
oms.  Patients  with  advanced  dementia  were  excluded  from
he  study.  The  data  from  questionnaires  were  validated
gainst  any  medical  reports  available  on  the  hospital  medi-
al  database,  to  correct  any  error  or  approximation.
Ischaemic  heart  disease  was  deﬁned  as  history  of  acute
oronary  syndromes  and/or  the  presence  of  signiﬁcant  coro-
ary  lesions.  History  of  heart  failure  was  deﬁned  as  previous
ospitalization  for  acute  pulmonary  oedema  or  right  heart
ailure  or  signiﬁcant  exertional  dyspnoea  (New  York  Heart
ssociation  class  II).  Chronic  respiratory  disease  was  deﬁned
s  chronic  restrictive  or  obstructive  pulmonary  disease.  We
earched  for  evidence  of  a  primary  or  secondary  cause  of
HD,  including  valvular  prolapse,  active  or  previous  infec-
ious  endocarditis,  rheumatic  heart  disease  or  history  of
heumatic  fever,  radiation-induced  VHD,  congenital  disease,
ssociated  connective  disease  and/or  vasculitis,  ischaemic
r  ventricular  dilatation-associated  regurgitation.  We  iden-
iﬁed  patients  with  a  history  of  valve  surgery  and  gathered
he  type  of  surgery  performed  and  the  pattern  of  valvular
esions.
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oppler echographic data
chocardiography  was  performed  for  each  patient  who
eported  exposure  to  fenﬂuramine  or  its  derivatives.  All
f  the  usual  echocardiographic  parameters  were  analysed,
ith  special  attention  to  valve  aspects  and  pulmonary  pres-
ure  evaluation.  We  applied  the  criteria  for  the  diagnosis
f  drug-induced  VHD  identiﬁed  in  a  French  multicentre
egistry  [3,9],  which  included:  leaﬂets  and  subvalvular  appa-
atus  thickening  and  retraction,  leaﬂets  loss  of  coaptation,
o  calciﬁcation  and  no  stenosis.  Before  the  diagnosis  of
ighly  probable  drug-induced  valvulopathy  could  be  made,
ther  causes  of  restrictive  VHD  were  excluded,  in  particu-
ar  remodelling  of  the  left  ventricle  and  rheumatic  heart
isease.  We  retained  the  following  criteria  as  indicating
ighly  probable  drug-induced  valvulopathy:  pure  regurgita-
ion,  no  calciﬁcation,  leaﬂets  retraction  without  signiﬁcant
eft  ventricular  dysfunction  in  the  case  of  mitral  regurgi-
ation,  no  dilatation  of  the  ascending  aorta  in  the  case
f  aortic  regurgitation.  We  thought  that  thickening  and
educed  mobility  of  leaﬂets,  and  thickening  of  subvalvular
pparatus  were  more  difﬁcult  to  establish.  We  retained  the
ollowing  criteria  as  indicating  unlikely  drug-induced  valvu-
opathy:  stenosis,  calciﬁcations,  and  commissural  fusions  in
he  case  of  mitral  regurgitation.  Mitral  and  aortic  regurgi-
ations,  which  did  not  match  with  criteria  for  either  highly
robable  or  unlikely  drug-induced  valvulopathy,  were  con-
idered  as  possible  drug-induced  valvulopathies.  PAH  was
onsidered  signiﬁcant  when  >  40  mmHg.  Patients  who  had
istory  of  valve  surgery  were  included  only  if  the  valvu-
opathy  was  discovered  ≥  3  months  after  the  start  of  the
rug.
Several  options  were  considered  for  obtaining  echocar-
iographic  data.  For  patients  admitted  to  the  intensive
are  unit,  transthoracic  echocardiography  images  taken
n  admission  were  recovered.  Patients  admitted  to  the
ospitalization  unit  were  referred  for  echocardiographic
xamination  at  the  echocardiography  laboratory.  If  an
chocardiogram  could  not  be  performed,  we  gathered  the
chocardiographic  data  available  on  the  hospital  inter-
al  network.  In  the  absence  of  any  such  information,  we
ontacted  the  out-of-hospital  cardiologist  to  obtain  any
chocardiographic  data,  as  accurately  as  possible  in  the  case
f  valvular  lesions.  The  echocardiography  equipment  used
ncluded:  Aloka,  Philips  iE33,  General  Electric  VIVID7  and
eneral  Electric  VIVID9.
All  of  the  available  echocardiographic  information  was
nalysed,  irrespective  of  when  the  scans  were  performed.
ransesophageal  echocardiography  images,  when  available,
ere  preferred  for  the  analysis  of  valves.  In  patients  with  a
istory  of  valve  surgery,  we  sought  to  investigate  the  type
f  VHD  at  the  time  of  surgery.  Echocardiographic  evaluation
riteria  were  those  established  by  the  American  Society  of
chocardiography  [10].
tatistical analysislinical  and  echocardiographic  characteristics  were
xpressed  as  mean  and  95%  CI  for  continuous  variables  and
s  counts  and  percentages  for  non-continuous  variables.
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Table  1  Patients’  clinical  characteristics.
Patients  (n  =  95)
Demographic  data
Women  62/95  (65.3)
Age  (years)  66.8  ±  2.5
BMI  (kg/m2) 29.5  ±  1.2
Cardiovascular  risk  factors
Past  or  current  smoker  43/95  (45.7)
Hypertension  68/95  (72.3)
Dyslipidaemia  64/95  (68.1)
Diabetes  mellitus 50/95  (53.2)
Clinical  data
Coronary  artery  disease 47/95  (49.5)
Atrial  ﬁbrillation  22/95  (23.2)
Heart  failure  25/95  (26.3)
Lung  disease 19/95  (20.2)
Chronic  renal  failure 24/95  (25.8)
Rheumatic  fever 3/95  (3.3)
Infectious  endocarditis 2/95  (2.1)
Autoimmune  disease 6/95  (6.4)
Radiotherapy  6/95  (6.5)
Neoplasia  20/95  (21.5)
Reason  for  admission
Acute  coronary  syndrome 14/95  (15.4)
Angina  12/95  (13.2)
Positive  stress  test  15/95  (16.5)
Coronary  angioplasty  2/95  (2.2)
Heart  failure  17/95  (18.7)
Assessment  of  valvulopathy  8/95  (8.8)
Pulmonary  artery  hypertension  5/95  (5.5)
Infectious  endocarditis  1/95  (1.1)
Atrial  ﬁbrillation  5/95  (5.5)
Symptoms
Dyspnoea  68/95  (71.6)
Chest  pain  56/95  (58.9)
Palpitations  36/95  (37.9)
History  of  valve  surgery  17/95  (18.7)
Valve  intervention
Mitral  valve  replacement  3/17  (17.6)
Mitral  valve  repair  2/17  (11.8)
Mitral  valve  dilatation  1/17  (5.9)
Aortic  valve  replacement  8/17  (47.1)
Aortic  valve  dilatation  2/17  (11.8)
TAVI  4/17  (23.5)
Tricuspid  valve  repair  1/17  (5.9)
Valve  disease
Mitral  regurgitation  3/17  (17.6)
Mitral  stenosis 1/17  (5.9)
Aortic  regurgitation 3/17  (17.6)
Aortic  stenosis  10/17  (58.8)
Data are number (%) or mean ± standard deviation. BMI: body
mass index; TAVI: transcatheter aortic valve implantation.
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Results
Study population and clinical data
The  study  involved  95  patients  who  completed  the  ques-
tionnaires  (Table  1).  There  was  predominance  of  women
(65.3%)  and  the  mean  age  was  66.8  (95%  CI  64.2—69.3)  years.
Most  patients  were  overweight,  with  a  mean  body  mass
index  (BMI)  of  29.5  (95%  CI  28.3—30.7)  kg/m2.  The  most  com-
mon  comorbidities  were  hypertension  (72.3%),  dyslipidemia
(68.1%),  diabetes  mellitus  (53.2%)  and  coronary  artery  dis-
ease  (49.5%).  Hospitalization  was  linked  to  the  management
of  coronary  artery  disease  in  47.3%  of  patients,  heart  failure
in  18.7%  and  VHD  in  8.8%.
Thirty-two  patients  (34.0%)  had  known  VHD;  5  patients
(5.3%)  had  heart  disease  ofﬁcially  linked  to  fenﬂuramine  or
a  derivative  (PAH  in  4  patients  and  aortic  regurgitation  in
1  patient).  Sixty-eight  patients  (71.6%)  reported  dyspnoea,
58.9%  chest  pain  and  37.9%  palpitations.  Seventeen  patients
(18.7%)  reported  surgical  or  percutaneous  valve  interven-
tions  that  had  already  been  completed  or  were  scheduled;
the  distribution  of  different  types  of  surgery  is  summarized
in  Table  1.  The  most  common  intervention  was  surgical  aor-
tic  valve  replacement  and  the  most  common  heart  valve
disease  was  aortic  stenosis.  Two  of  the  three  cases  of  aor-
tic  regurgitation  were  caused  by  infective  endocarditis.
Excluding  infective  endocarditis,  surgical  or  percutaneous
valve  interventions  for  mitral  or  aortic  regurgitations  were
reported  in  3  of  95  (3.2%)  patients.
Treatment
Of  the  95  patients,  90.5%  had  been  treated  with  benﬂuo-
rex,  35.8%  with  dexfenﬂuramine  and  1.1%  with  fenﬂuramine
(Table  2).  Twenty-ﬁve  patients  (26.3%)  had  been  exposed
to  both  benﬂuorex  and  dexfenﬂuramine.  The  primary  indi-
cation  for  treatment  was  overweight,  followed  by  diabetes
mellitus;  misuse  of  benﬂuorex  was  reported  in  a  large  pro-
portion  of  the  population  (47.7%).  Treatment  was  initiated
after  1997  (date  of  withdrawal  of  dexfenﬂuramine)  in  36.0%
of  patients.  The  mean  duration  of  treatment  was  52.3
(95%  CI  39.0—65.6)  months,  and  90.5%  had  been  exposed
for  ≥  3  months  and  31.6%  for  ≥  5  years.
Treatment  was  most  commonly  prescribed  by  a  general
practitioner  (75.8%  of  patients),  followed  by  an  endocrinol-
ogist  (15.8%  of  patients),  and  by  a  cardiologist  in  only  3.2%
of  patients  (Table  2).  The  drug  was  taken  without  a  prescrip-
tion  in  3.2%  of  patients.  Cardiologists  were  the  most  likely
to  discontinue  medication  (10.5%),  followed  by  endocrinolo-
gists  (8.4%),  whereas  general  practitioners  were  least  likely
to  discontinue  it  (0.4%);  34.7%  of  patients  discontinued  the
treatment  without  medical  advice.  The  main  reasons  given
for  treatment  discontinuation  were  intolerance  and  inefﬁ-
ciency.
Echocardiographic data
Doppler  echocardiogram  images  were  available  for  75
patients.  In  18  of  the  20  patients  without  echocardiogram
images,  echocardiographic  reports  were  retrieved  from
the  hospital  medical  database  (11  patients,  61.1%)  or  the
patient’s  cardiologist  (7  patients,  38.9%).  Six  patients  had
(
p
ao  echocardiographic  data  available  (images  or  reports)
Table  3).Mitral  valve  abnormalities  were  found  in  54  (61.4%)
atients,  aortic  valve  abnormalities  in  47  (54.0%)  patients,
nd  both  abnormalities  in  41.4%  (Table  4).  Both  mild  mitral
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Table  2  Treatment  characteristics.
Patients  (n  =  95)
Anorexigens  use
Benﬂuorex  86/95  (90.5)
Dexfenﬂuramine  34/95  (35.8)
Fenﬂuramine  1/95  (1.1)
Fenﬂuramine  derivatives  treatment
Indication
Diabetes  mellitus 37/95  (38.9)
Hypertriglyceridaemia  15/95  (15.8)
Obesity  57/95  (60.0)
Benﬂuorex  misuse  (for  overweight)  41/95  (47.7)
Treatment  initiation
General  practitioner  72/95  (75.8)
Endocrinologist  15/95  (15.8)
Cardiologist  3/95  (3.2)
Treatment  discontinuation
General  practitioner  42/95  (0.4)
Endocrinologist  8/95  (8.4)
Cardiologist  10/95  (10.5)
Patient  33/95  (34.7)
Reason  for  discontinuation
Intolerance  14/93  (15.1)
Inefﬁciency  16/93  (17.2)
Withdrawal  10/93  (10.8)
Cardiotoxicity  10/93  (10.8)
Valvulopathy  1/93  (1.1)
Satisfactory  weight  loss  10/93  (10.8)
Change  of  antidiabetic  therapy  5/93  (5.4)
Unknown  20/93  (21.5)
Other  8/93  (8.6)
Total  duration  of  therapy  (months)  52.3  ±  13.3
Beginning  after  1997  32/89  (36.0)
Duration  ≥  3  months  86/95  (90.5)
Duration  ≥  5  years  30/95  (31.6)
No  prescription 3/94  (3.2)
Data are number (%) or mean ± standard deviation.
Table  3  Doppler  echocardiographic  data.
Patients  (n  =  95)
Echocardiography  equipmenta
Medical  ICU,  ALOKA  30/95  (31.6)
Laboratory,  Philips  iE33  21/95  (22.1)
Laboratory,  VIVID  40/95  (42.1)
Surgical  ICU,  VIVID  1/95  (1.1)
Consultation,  VIVID  5/95  (5.3)
Echocardiography  dataa
TTE  or  TOE  75/95  (78.9)
TOE  20/95  (21.1)
No  TTE/TOE  image  20/95  (21.1)
No  TTE/TOE  data  6/95  (6.3)
Data are number (%). ICU: intensive care unit; TTE: transthoracic
echocardiography; TOE: transoesophageal echocardiography.
a Categories are not mutually exclusive.
Table  4  Echocardiographic  ﬁndings.
Patients  (n  =  95)
Mitral  valve  abnormalities  54/88  (61.4)
Thickening  11/80  (13.8)
Calciﬁcations  18/81  (22.2)
Commissural  fusion  5/54  (9.3)
Drumstick  appearance  4/80  (5.0)
Thickening  of  subvalvular  apparatus  9/76  (11.8)
Reduced  mobility  8/79  (10.1)
Retraction  21/81  (25.9)
Prolapse  0/82  (0.0)
Regurgitation 47/89  (52.8)
Mild  44/87  (50.6)
Moderate  to  severe  3/89  (3.4)
Stenosis  8/88  (9.1)
Mild  to  moderate  7/88  (8.0)
Severe  1/88  (1.1)
LVEF
LVEF  ≥  55%  59/89  (66.3)
55%  >  LVEF  ≥  45% 17/89  (19.1)
45%  >  LVEF  ≥  30% 10/89  (11.2)
LVEF  <  30% 3/89  (3.4)
Left  ventricular  dilation 9/88  (10.2)
Left  atrial  enlargement 33/87  (37.9)
Aortic  valve  abnormalities 47/87  (54.0)
Bicuspid  valve 2/45  (4.4)
Thickening  15/84  (17.9)
Calciﬁcations  20/85  (23.5)
Loss  of  coaptation 10/83  (12.0)
Reduced  mobility 11/83  (13.3)
Retraction  11/83  (13.3)
Regurgitation  38/87  (43.7)
Mild  31/87  (35.6)
Moderate  to  severe  7/83  (8.0)
Stenosis  13/89  (14.6)
Mild  to  moderate  2/88  (2.3)
Severe  11/89  (12.4)
Dilatation  of  ascending  aorta  5/88  (5.7)
Right  heart  ﬁndings
Tricuspid  valve  regurgitation  59/84  (70.2)
Mild  49/81  (60.5)
Moderate  to  severe  10/84  (11.9)
Tricuspid  valve  stenosis  0/86  (0.0)
PAH  17/86  (19.8)
Systolic  pulmonary  pressure  (mmHg)  58.1  ±  3.3
PAH  with  LVEF  ≥  45%  12/86  (14.0)
Right  ventricular  enlargement  9/87  (10.3)
Right  ventricular  systolic  dysfunction  8/86  (9.3)
Left  heart  valves  abnormalities  64/87  (73.6%)
Both  mitral  and  aortic  valves  36/87  (41.4)
Mitral  or  aortic  valve 64/87  (73.6)
Neither  mitral  nor  aortic  valves  23/87  (26.4)
Restrictive  mitral  regurgitation,
LVEF  ≥  45%,  no  stenosis,  no
calciﬁcation
8/80  (10.0)
Restrictive  aortic  regurgitation,  no
aortic  dilatation,  no  stenosis,  no
calciﬁcation
11/83  (13.3)
Data are number (%) or mean ± SD. LVEF: left ventricular
ejection fraction; PAH: pulmonary arterial hypertension.
Characteristics  after  exposure  to  fenﬂuramin  derivatives  
Table  5  Distribution  of  regurgitations.
Overall  popula
(n  =  95)
Highly  probable  drug-induced  regurgitations  16/86  (18.6)  
Possibly  drug-induced  regurgitations  34/89  (38.2)  
Unlikely  drug-induced  regurgitations  23/89  (25.8)  
Data are number (%).
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mregurgitation  and  mild  aortic  regurgitation  were  found  in  22
patients  (25.9%).  No  patient  had  both  moderate  to  severe
mitral  regurgitation  and  mild  aortic  regurgitation.  Both  mild
mitral  regurgitation  and  moderate  to  severe  aortic  regurgi-
tation  were  found  in  4  patients  (4.8%).  One  patient  (1.2%)
had  both  moderate  to  severe  mitral  and  aortic  regurgitation.
Calciﬁcations  of  the  valvular  tissue  were  common.  Twenty-
three  patients  were  free  of  left  VHD  (26.4%).  Left  ventricular
ejection  fraction  (LVEF)  was  >  45%  in  most  patients  (n  =  76,
85.4%).
Mitral  regurgitation  was  identiﬁed  in  47  (52.8%)  patients,
and  was  moderate  to  severe  in  3.4%  (Table  4).  Restrictive
mitral  regurgitation  with  LVEF  ≥  45%  and  without  steno-
sis  or  calciﬁcation  of  the  leaﬂet  tissue  was  seen  in  8
(10.0%)  patients.  Mitral  regurgitation  in  this  subgroup  was
considered  as  highly  probable  drug-induced  VHD,  and  was
moderate  to  severe  in  1  patient.  The  transthoracic  echocar-
diogram  from  this  patient  had  shown  left  ventricular
dilatation  (end-diastolic  diameter  59  mm)  with  normal  walls
and  hyperkinesis  (LVEF  69%),  dilatation  of  the  left  atrium
(surface  area  32  cm2),  severe  mitral  regurgitation  (effec-
tive  regurgitant  oriﬁce  area  [EROA]  31  mm2 and  regurgitant
volume  56  mL)  with  reduced  mobility  of  leaﬂets,  severe  aor-
tic  regurgitation  without  leaﬂets  retraction,  PAH  (systolic
pulmonary  artery  pressure  52  mmHg),  and  a  dilated  inferior
vena  cava.  The  male  patient  was  born  in  1941,  had  under-
gone  mechanical  valve  replacement  of  both  the  mitral  and
the  aortic  valve  in  2007,  had  type  2  diabetes  and  had  been
exposed  to  benﬂuorex  for  12  months.
Aortic  regurgitation  was  identiﬁed  in  38  (43.6%)  patients,
and  was  moderate  to  severe  in  8.0%  (Table  4).  Restrictive
aortic  regurgitation  with  neither  dilatation  of  ascending
aorta  nor  stenosis  of  calciﬁcation  of  the  cusp  tissue  was
described  in  11  (13.3%)  patients.  Aortic  regurgitation  in  this
subgroup  was  considered  as  highly  probable  drug-induced
aortic  VHD,  and  was  moderate  to  severe  in  2  patients.
For  the  ﬁrst  patient,  transthoracic  and  transesophageal
echocardiograms  had  shown  a  normal  left  ventricle,  dilata-
tion  of  the  left  atrium,  mild  mitral  regurgitation  with  leaﬂets
retraction,  moderate  aortic  regurgitation  (vena  contracta
4.5  mm,  proximal  isovelocity  surface  area  4.8  mm)  with
thickened  leaﬂets  and  central  loss  of  coaptation,  and  no
PAH.  This  female  patient  was  born  in  1960,  had  type  2
diabetes,  coronary  heart  disease  and  end-stage  kidney  dis-
ease  with  a  history  of  renal  transplantation.  She  had  been
exposed  to  benﬂuorex  for  6  years.  For  the  second  patient,
transthoracic  and  transesophageal  echocardiograms  had
shown  left  ventricular  dilatation  (end-diastolic  diameter
54  mm)  with  normal  walls  and  normal  LVEF  (62%),  dilata-
tion  of  the  left  atrium  (surface  area  23  cm2),  mild  mitral
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Patients  with  aortic
regurgitation
8/80  (10.0)  11/83  (13.3)
24/89  (27.0)  15/88  (17.0)
15/89  (16.9)  12/89  (13.5)
egurgitation  (EROA  11  mm2 and  regurgitant  volume  15  mL)
ith  normal  leaﬂets,  moderate  aortic  regurgitation  (vena
ontracta  5.4  mm,  EROA  13  mm2 and  regurgitant  volume
7  mL)  with  central  loss  of  coaptation,  and  no  pulmonary
rterial  hypertension.  This  female  patient  was  born  in  1934,
ad  arterial  hypertension  and  atrial  ﬁbrillation.  She  had
een  exposed  to  benﬂuorex  for  13  years.  Right  heart  ﬁndings
re  summarized  in  Table  4.
Mild  tricuspid  regurgitation  was  found  in  49  (60.5%)
atients,  and  moderate  to  severe  tricuspid  regurgitation
n  10  (11.9%)  patients  (Table  4).  PAH  with  LVEF  ≥  45%  was
resent  in  12  (14.0%)  patients.  A  highly  probable  drug-
nduced  VHD  was  associated  with  PAH  in  2  (2.4%)  patients,
oth  of  whom  had  highly  probable  drug-induced  mild  aortic
egurgitation.
In  total,  mitral  regurgitation  and/or  aortic  regurgitation
as  found  57  (64.0%)  patients.  Highly  probable  drug-induced
itral  and/or  aortic  valve  disease  was  described  in  16
18.6%)  patients  (Table  5).  An  unlikely  drug-induced  mitral
nd/or  aortic  valve  disease  was  identiﬁed  in  23  (25.8%)
atients.  A  possible  drug-induced  mitral  and/or  aortic  valve
isease  was  found  in  34  (38.2%)  patients.  Simultaneous
nvolvement  of  highly  probable  drug-induced  mitral  and  aor-
ic  VHD  was  uncommon,  and  was  present  in  3  of  77  (3.9%)
atients.  No  left  heart  valvular  abnormality  was  identiﬁed  in
3  of  87  (26.4%)  patients.  One  patient  with  a  history  of  valve
urgery  (combined  mitral  and  aortic  valve  replacement)  had
 highly  probable  drug-induced  VHD.
iscussion
he  proﬁle  of  patients  exposed  to  fenﬂuramine  or  its  deriva-
ives  was  similar  to  that  in  the  published  literature  [1—3].
onsumers  of  fenﬂuramine  or  its  derivatives  were  mainly
iddle-aged  overweight  women.  Benﬂuorex  was  used  off-
abel,  for  treatment  of  overweight,  in  47.7%  of  patients.
his  frequency  was  estimated  at  20%  by  the  investigation
eport  of  the  General  Inspectorate  of  Social  Affairs.  More
han  90%  of  patients  had  been  exposed  to  fenﬂuramine  or
ts  derivatives  for  ≥  3  months,  which  was  the  minimum  time
uring  which  valvular  abnormalities  appeared  in  the  CNAM
tudy  [7].  The  most  frequent  prescribers  of  fenﬂuramine
r  its  derivatives  were  general  practioners,  whereas  car-
iologists  were  the  least  likely  to  initiate  them  and  the
ost  likely  to  discontinue  them.  Treatment  was  initiated
fter  the  withdrawal  from  the  market  of  dexfenﬂuramine
n  a  sizeable  proportion  of  patients,  in  spite  of  the  fact
hat  the  cardiotoxicity  of  fenﬂuramine  or  its  derivatives
ad  already  been  established.  Moreover,  only  10.8%  of
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iscontinuations  were  driven  by  the  knowledge  of  their  car-
iotoxicity.  These  statements  highlight  the  lack  of  reactivity
f  French  drug-control  agencies  to  stop  prescription  of  these
rugs.  Consumption  without  medical  prescription  was  very
are  (3.2%),  as  suggested  by  the  wide  off-label  use  (for  over-
eight)  of  benﬂuorex.
Most  patients  were  highly  symptomatic,  which  likely
eﬂects  their  high  prevalence  of  comorbidities.  The  study
roup  comprised  patients  at  high  cardiovascular  risk  who
ere  clearly  at  greater  risk  of  atherosclerosis  than  those
n  the  CNAM  study  [7]  (diabetes  mellitus  53.2%  vs  33%  in
NAM,  hypertension  72.3%  vs  15.5%,  coronary  artery  dis-
ase  49.5%  vs  15.5%).  The  Framingham  study  [11]  reported
 higher  risk  of  developing  mitral  insufﬁciency  in  individ-
als  with  hypertension  (hazard  ratio  1.6,  95%  CI  1.2—2.0).
hanassoulis  et  al.  [12]  showed  an  association  between  a
igher  Framingham  score  and  the  prevalence  and  severity  of
ortic  valve  calcium.  Anvari  et  al.  [13]  reported  that  valvu-
ar  atherosclerotic  changes  were  strongly  analogous  with
oronary  atherosclerosis  and  generalized  atherosclerotic
rocesses.  Anvari  et  al.  [13]  found  that  BMI,  smoking  habit,
iabetes  and  aortic  stenosis  were  risk  factors  for  valvular
therosclerosis.  The  aspect  of  valvular  abnormalities  asso-
iated  with  atherosclerosis  is  still  quite  different  from  that
ssociated  with  drug-induced  valvulopathies,  because  of  the
resence  of  valvular  calciﬁcations.
Mitral  and  aortic  valve  abnormalities  were  frequent  in
he  present  study,  affecting  nearly  three-quarters  of  our
opulation  with  past  exposure  to  fenﬂuramine  or  its  deriva-
ives.  The  frequency  of  valve  abnormalities  was  high  in
he  REGULATE  study  [5],  even  before  exposure  to  benﬂuo-
ex,  with  at  least  one  morphological  valvular  abnormality
n  51%  of  patients  and  at  least  one  functional  valvular
bnormality  in  84%  of  patients.  The  rates  of  mitral  and
ortic  regurgitations  observed  in  our  study  are  higher  than
hose  reported  in  the  Framingham  study  [11],  respectively,
3.9%  versus  38.1%  and  43.7%  versus  21.5%.  Calciﬁcations
ere  common  and  were  found  in  >  20%  of  cases  for  both
itral  and  aortic  valves  in  this  relatively  old  population,
ho  were  as  a  consequence  more  prone  to  degenerative
HD.  This  ﬁnding  highlights  the  problem  of  toxic  valvu-
opathies  that  would  have  degenerated,  with  the  possible
evelopment  of  stenotic  calciﬁcations,  making  it  impossi-
le  to  recognize  the  pattern  of  drug-induced  VHD.  It  is  also
onceivable  that  drug-induced  valvular  lesions  could  pro-
ote  valve  degeneration.  While  >  90%  of  the  patients  were
xposed  to  benﬂuorex  for  ≥  3  months,  greater  than  one-
uarter  did  not  have  a  left  heart  valvular  abnormality,  which
orroborates  the  hypothesis  of  individual  susceptibility  to
eveloping  the  lesion  [6].  However,  some  studies  have  found
o  association  between  VHD  and  fenﬂuramines.  Hepp  et  al.
14]  and  Davidoff  et  al.  [15]  performed  echocardiographic
omparative  studies  that  showed  no  difference  between
atients  exposed  or  not.  A  randomized  double-blind  study
y  Weissman  et  al.  [16]  showed  only  a slight  increase  in
on-signiﬁcant  mitral  and  aortic  regurgitations,  similar  to
‘physiological’’  leaks.  These  abnormalities  were  no  longer
resent  3—5  months  after  stopping  treatment  [17].Tricuspid  valve  involvement  is  rare  in  the  literature
n  drug-induced  VHD  [18].  In  our  population,  moderate
o  severe  tricuspid  regurgitations  were  not  associated
ith  signiﬁcant  morphological  abnormalities.  In  the  French
o
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ulticentre  registry  [3], moderate  to  severe  tricuspid
egurgitations  were  mostly  secondary  to  PAH  and  annulus
ilatation;  PAH  was  identiﬁed  in  50%  of  patients  suffering
rom  unexplained  restrictive  valvular  disease  with  a  previ-
us  exposure  to  benﬂuorex.  In  contrast,  PAH  was  uncommon
n  our  study  and  was  associated  with  a highly  probable  drug-
nduced  VHD  in  only  2.4%  of  patients.  According  to  the
nternational  Primary  PAH  Study  [19],  the  relative  risk  of
AH  associated  with  the  use  of  at  least  one  anorectic  was
.8.  The  annual  incidence  of  PAH  in  the  general  population
s  approximately  1—2  cases  per  1  million  persons  and  the
isk  of  developing  PAH  is  multiplied  by  30  during  an  expo-
ure  of  ≥  3  months  to  anorexigens.  In  our  study,  the  cases  of
AH  without  signiﬁcant  left  ventricular  dysfunction  (14.0%
f  patients)  could  not  be  attributed  to  fenﬂuramine  or  its
erivatives  because  patients  had  not  undergone  a  right  heart
atheterization.  The  pulmonary  valve  is  rarely  considered  in
he  literature  on  drug-induced  VHD.  This  also  applies  to  our
tudy.
In  total,  a  highly  probable  drug-induced  mitral  and/or
ortic  valve  disease  was  described  in  18.6%  of  patients.
hese  regurgitations  were  mild  in  over  four-ﬁfths  of  the
atients  and  one  patient  had  a  history  of  valve  surgery.  This
atient  stated  that  no  one  had  suggested  a link  between
ast  exposure  to  fenﬂuramine  or  its  derivatives  and  his  VHD.
his  case  illustrates  the  potential  severity  of  drug-induced
HD,  highlighted  by  the  French  multicentre  registry  [3].
urger  et  al.  [20]  reported  that  phentermine—fenﬂuramine
herapy  was  associated  with  a  low  prevalence  of  signiﬁ-
ant  valvular  regurgitation,  similar  to  the  normal  offspring
n  the  Framingham  Heart  Study  [11].  Obviously,  the  num-
er  of  signiﬁcant  regurgitations  in  our  population  does  not
xplain  the  frequency  of  history  of  heart  failure,  found  in
6.3%  of  patients.  It  is  certainly  difﬁcult  to  quantify  the
isk  of  severe  VHD  attributable  to  benﬂuorex  and  lead-
ng  to  heart  failure  and/or  surgery  and/or  death  of  the
atient.  This  was  the  aim  of  the  statistical  survey  conducted
y  CNAM  [7], based  on  two  national  medicoadministra-
ive  databases  that  used  ICD-10  diagnostic  codes,  whose
abels  were  insufﬁcient  to  describe  drug-induced  valvular
egurgitations.  They  only  determine  the  location  of  the  dam-
ged  valve  and  the  type  of  lesion,  whether  rheumatic  or
on-rheumatic.
We  could  not  determine  the  ratio  between  the  number
f  patients  with  highly  probable  drug-induced  valve  dis-
ase  and  the  total  number  of  patients  hospitalized  during
he  period  of  study  because  the  questionnaire  could  not
e  given  to  all  patients.  It  is  awkward  to  compare  the  fre-
uency  of  VHD  observed  in  our  study  with  that  reported  in
he  literature,  as  the  study  design  is  very  different.  Fra-
hon  et  al.  [1]  and  Tribouilloy  et  al.  [2]  conducted  two
ase-control  studies  in  order  to  assess  the  rates  of  exposure
o  benﬂuorex  in  patients  with  restrictive  mitral  regurgita-
ions  of  unclear  aetiology  compared  with  matched  controls.
he  CNAM  survey  [7]  sought  to  estimate  the  risk  of  hos-
italization  for  assessment  of  VHD  and  the  risk  of  valve
eplacement  in  patients  treated  with  benﬂuorex  and  iden-
iﬁed  by  linking  two  databases:  the  information  system
f  the  Health  Insurance  Fund  for  Salaried  Workers  (SNI-
RAM)  and  the  French  hospital  discharge  database  (PMSI).
he  echocardiographic  features  of  these  valvulopathies
ere  not  considered.  The  French  multicentre  registry  [3]
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retrospectively  identiﬁed  patients  with  unexplained  and
moderate  to  severe  VHD  with  a  previous  exposure  to  benﬂu-
orex.  Conversely,  the  design  of  our  study  is  quite  similar
to  that  used  in  the  latest  prospective  multicentre  study
by  Tribouilloy  et  al.  [21],  which  included  835  subjects
previously  exposed  to  benﬂuorex.  Drug-induced  VHD  was
less  frequent  in  this  population  referred  by  primary  care
physicians  and  6.8%  of  patients  were  classiﬁed  as  ‘‘drug-
induced  VHD  (+)’’  versus  18.6%  in  our  study.  Mitral  and
aortic  drug-induced  VHD  were  reported  in  5.1%  and  3.6%
of  patients,  respectively,  versus  10.0%  and  13.3%  in  our
study.
A  history  of  surgical  or  percutaneous  valve  interven-
tions  was  reported  in  18.7%  of  patients;  and  almost  half
had  aortic  stenosis.  Surgical  or  percutaneous  valve  inter-
ventions  for  mitral  or  aortic  regurgitations  were  uncommon
(3.2%).  In  our  cohort,  fenﬂuramine  or  its  derivatives  could
not  be  held  responsible  most  of  the  valve  interventions.
The  CNAMTS  survey  [7]  reported  a  rate  of  hospitalization
for  valvular  complications  and/or  PAH  not  exceeding  1 per
1000/year  in  patients  exposed  to  benﬂuorex.  The  size  of
our  population  might  not  be  sufﬁcient  to  demonstrate  an
association.
Echocardiograms  were  performed  in  the  University  Hos-
pital  of  Montpellier  in  only  78.9%  of  patients.  This  is  partly
explained  by  the  absence  of  slot  allocation  reserved  for
this  study  at  the  echocardiography  laboratory.  The  accu-
racy  of  the  analysis  of  valves  was  variable  depending  on  the
available  data.  After  examination  of  information  retrieved
from  both  hospital  medical  database  and  echocardiogram
reports  from  the  usual  cardiologists,  only  6  patients  (6.3%)
had  no  echocardiographic  data  available.  The  absence  of
a  double-blind  review  of  the  echocardiograms  is  a  limita-
tion  of  our  study,  even  though  analysis  of  the  images  was
very  thorough.  Moreover,  variables  that  were  not  properly
assessable  were  reported  as  such.  Excluding  the  determina-
tion  of  commissural  fusion  and  bicuspid  aortic  valve  (which
was  possible  in  only  half  of  the  patients),  echocardiographic
parameters  could  be  evaluated  in  >  80%  of  the  95  patients
included.  Finally,  our  study  is  descriptive  only  and  cannot
prove  a  direct  relationship  between  drug  consumption  and
presence  or  severity  of  drug-induced  VHD.
Conclusion
Valvulopathies  were  frequent  among  patients  admitted  to
our  hospitalization  and  intensive  care  units  and  who  had  past
exposure  to  fenﬂuramine  or  its  derivatives.  Highly  probable
drug-induced  valvulopathies  affected  18.6%  of  patients  but
in  most  cases  regurgitation  was  mild.  Causation  is  difﬁcult
to  prove,  however,  given  the  non-speciﬁc  echocardiogra-
phic  aspects  of  drug-induced  VHD.  No  score  for  diagnosis
has  yet  been  established.  Degenerative  VHD  in  this  high-
risk  population  is  therefore  not  excluded  and  explained
most  cases  of  surgical  and  percutaneous  valve  interven-
tions.  Considering  the  frequency  and  in  the  absence  of
deﬁnite  knowledge  about  the  evolution  of  these  valve  dis-
eases,  systematic  questioning  concerning  fenﬂuramine  or
derivative  use  should  be  considered  in  hospitalized  cardiac
patients.
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